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ABSTRACT
The role of percutaneous balloon aortic valvuloplasty
(BAV) in the management of severe symptomatic aortic
stenosis has come under the spotlight following the
development of the transcatheter aortic valve
implantation (TAVI) technique. Previous indications for
BAV were limited to symptom palliation and as a bridge
to definitive therapy for patients undergoing
conventional surgical aortic valve replacement (AVR).
In the TAVI era, BAV may also be undertaken to assess
the ‘therapeutic response’ of a reduction in aortic
gradient in borderline patients often with multiple
comorbidities, to assess symptomatic improvement
prior to consideration of definitive TAVI intervention.
This narrative review aims to update the reader on the
current indications and practical techniques involved in
undertaking a BAV procedure. In addition, a summary
of the haemodynamic and clinical outcomes, as well as
the frequently encountered procedural complications is
presented for BAV procedures conducted during both
the pre-TAVI and post-TAVI era.
INTRODUCTION
Percutaneous balloon aortic valvuloplasty
(BAV) was widely adopted when ﬁrst
described by Cribier et al1 in 1986, as a
simple low-cost treatment strategy for patients
with symptomatic severe aortic stenosis (AS)
presenting in cardiogenic shock, or for
symptom palliation in those considered too
frail for conventional surgical aortic valve
replacement (AVR) surgery. Its popularity
waned however, as it emerged that restenosis
and recurrence of symptoms were common
after 6 months and mortality rates within a
year of BAV were similar to those of an
untreated conservatively managed
population.2
In 2002, Cribier introduced his deﬁnitive
solution for inoperable patients with severe
AS—the ﬁrst-in-man transcatheter aortic
valve implantation (TAVI).3 Since then, the
PARTNER trials have demonstrated the
superiority of TAVI in comparison to optimal
medical therapy (OMT), which included the
use of BAV. In patients not suitable for
surgery, all-cause mortality after 1 and 5 years
following TAVI was 30.7% and 71.8%, respect-
ively, compared with 50.7% and 93.5% for
those being treated with OMT.4 5 Similarly, in
high-risk individuals, both the PARTNER and
COREVALVE studies demonstrate that TAVI
confers similar symptomatic and prognostic
improvements when compared with conven-
tional surgical AVR (table 1).6–8
The evolution of TAVI into the treatment
of choice for high-risk and inoperable
patients with severe symptomatic AS has seen
a resurgence in the numbers of BAV proce-
dures being performed (ﬁgure 1). During a
TAVI procedure, BAV may be undertaken
prior to transcatheter heart valve (THV)
deployment to facilitate catheter and valve
delivery across the aortic annulus and may
also be used to minimise the likelihood of
coronary occlusion by the valve leaﬂets given
the close proximity of the ostia of the coron-
ary arteries to the annulus. BAV can play a
role in accurately measuring aortic annular
size in conjunction with transoesophageal
echo (TOE) or CT.9 This is particularly
useful in patients where the aortic annulus
size falls in the cut-off between two suitable
THV sizes and balloon valvuloplasty with a
similar sized balloon has been used in some
cases to assess the risks of coronary occlusion
and guide choices of THV size for TAVI intra-
procedurally. BAV may also be undertaken
post-THV deployment intraprocedurally to
improve valve expansion, in particular if
there is a suggestion of signiﬁcant paravalvu-
lar aortic regurgitation (AR) secondary to
annular calciﬁcation and consequent sub-
optimal THV expansion.
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Increasingly, borderline patients with poor left ven-
tricular (LV) systolic function, chronic obstructive pul-
monary disease (COPD), advanced comorbidities and
signiﬁcant frailty who are deemed too high risk to
undergo TAVI or AVR can undergo a BAV as a diagnostic
tool to assess ‘therapeutic response’ to a signiﬁcant
reduction in transaortic valvular gradient with a view to
a deﬁnitive procedure if a signiﬁcant beneﬁt can be
demonstrated. Finally, as individual operator experience
grows, BAV is likely to be offered more frequently in the
context of the original indications for BAV, principally
cardiogenic shock and symptom palliation. Combined
with an increasingly ageing population, the number of
BAV procedures is set to increase further over the next
few years.10
In one study of 99 patients with severe AS and
impaired left ventricular ejection fraction (LVEF) who
underwent TAVI, the role of BAV or dobutamine stress
echocardiography (DSE) were compared on the ability
to guide prognostic beneﬁt post-TAVI. Those patients
who had been identiﬁed to have contractile reserve on a
preprocedural DSE had a lower mortality than those
who did not have any reserve. DSE, however, was unable
to predict those patients in whom LVEF would improve
post-TAVI. Those patients with impaired Left Ventricular
Systolic Function (LVSF) who underwent BAV and
showed a subsequent improvement in LVSF were more
likely to show an improved LVEF post-TAVI as well. The
conclusion was that both DSE and BAV provided com-
plementary data with regard to the likelihood of LVEF
improvement post-TAVI together with mortality (both
periprocedurally and longer term).11
This narrative review discusses current guidelines and
indications for BAV, the procedure itself with its risks
and limitations, as well as contemporary and historical
clinical outcomes.
CURRENT EUROPEAN AND AMERICAN GUIDELINE
INDICATIONS FOR BAV
In the current European Society of Cardiology (ESC)
guidelines (2012), BAV has a class IIb indication for use
as a bridge therapy to TAVI or AVR in haemodynamically
unstable patients at high risk for surgery, or in patients
with symptomatic severe AS who require urgent non-
cardiac surgery (level of evidence: C).12 They additionally
recommend considering BAV as a palliative measure in
selected individuals not suitable for TAVI or AVR (table
2). Although the American Heart Association (AHA)/
American College of Cardiology (ACC) guidance (2014)
suggest that BAV may be considered as a bridge to TAVI
or AVR for patients with severe symptomatic AS (class IIb,
Table 1 Comparison of mortality rates between TAVI and
AVR from the PARTNER6 and COREVALVE7 8
Follow-up period
TAVI (all-cause
mortality) (%)
AVR (all-cause
mortality) (%)
30 days (PARTNER)6 3.4 6.5
1 year (PARTNER)6 24.2 26.8
1 year (COREVALVE)7 14.2 19.1
3 years
(COREVALVE)8
32.9 39.1
AVR, aortic valve replacement; TAVI, transcatheter aortic valve
implantation.
Table 2 Summary of ESC12 and AHA/ACC13 guidelines
for the role of BAV in managing severe aortic stenosis
Indication for BAV in severe
symptomatic aortic stenosis
ESC
(2012)
AHA/ACC
(2014)
As bridge therapy for all patients
undergoing TAVI or AVR
× ✓
As bridge therapy for
haemodynamically unstable patients
undergoing TAVI or AVR
✓ ✓
For patients requiring urgent
non-cardiac surgery
✓ ×
As a palliative procedure for
symptomatic benefit
✓ ×
AVR, aortic valve replacement; BAV, balloon aortic valvuloplasty;
ESC, European Society of Cardiology; TAVI, transcatheter aortic
valve implantation.
Figure 1 Number of balloon aortic valvuloplasty and TAVI
procedures in the UK—the increase in stand-alone BAV
mirrors the increase in TAVI (TAVI data from the 25 UK
centres with TAVI programmes—British Cardiovascular
Intervention Society 2011; BAV data from 14 study centres).
Reproduced having obtained permission from corresponding
author.15 BAV, balloon aortic valvuloplasty; TAVI,transcatheter
aortic valve implantation.
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level of evidence: C), unlike the European guidance they
do not recommend the use of BAV in patients undergo-
ing urgent non-cardiac surgery or as palliation but do
acknowledge that some patients report an improvement
in their symptoms (table 2).13
Both guidelines advocate for decision-making to be
undertaken by a multidisciplinary team (MDT), taking
into account individual patient characteristics and
comorbidities, prior to undertaking any procedures.
THE BAV PROCEDURE
BAV procedures should be undertaken in cardiac
centres by experienced operators, following a detailed
consent process, which highlights key risks associated
with the procedure. The indication for BAV including as
a palliative procedure, as a staged procedure prior to
potential TAVI/AVR or to facilitate urgent intermediate
or high-risk non-cardiac surgery should be clearly estab-
lished prior to any intervention.
Procedural beneﬁts and risks should be discussed with
patients. Procedural risks include vascular damage
requiring intervention or surgery (including haematoma,
haemorrhage, pseudoaneurysm, dissection and vascular
ischaemia), myocardial infarct, stroke, cardiac chamber
perforation, tamponade requiring cardiothoracic surgery
or pericardiocentesis, dysrhythmia, annular rupture,
aortic dissection, emergency cardiothoracic surgery and
mortality. Although contrast is used to prepare the aortic
balloon, the procedure can be undertaken with minimal
or no intravascular contrast use making it suitable in
patients with advanced renal disease.
Patients excluded from BAV include those with metal-
lic or bioprosthetic aortic valve (due to risk of fragmen-
tation of prosthetic apparatus), active aortic valve
endocarditis, those without severe AS, patients with pre-
existing severe AR or patients with signiﬁcant frailty and
comorbidity unsuitable for any other aortic valve inter-
vention and in whom BAV would not provide a signiﬁ-
cant change in quality or quantity of life. BAV may not
be suitable either in those patients in whom aortic
annular area is too small or too large for conventional
balloon sizes although again this is likely to be rare
given the variety of balloon sizes available. Patients with
LV thrombus in situ, signiﬁcant left main stem stenosis
or those with active bleeding that would prevent systemic
heparinisation intraprocedurally are also contraindicated
from BAV. Decision on BAV and any other aortic valve
interventions are best made via the decision of a multi-
disciplinary ‘heart team’ meeting which ideally should
involve interventional/structural cardiologists, imaging
cardiologists (echo/CT), cardiothoracic surgeons and if
appropriate physicians with interest in elderly care medi-
cine (given the abundance of AS in patients with
advanced age).
Prior to the BAV procedure, the operator should make
a decision, ideally in conjunction with the patient and
relatives about the ceiling of therapy to involve the
patient if there is a signiﬁcant or in particular cata-
strophic complication. Decisions need to involve
whether a patient is a candidate for emergency sternot-
omy, cardiopulmonary bypass or surgery so that a clear
plan can be made in case there is a procedural compli-
cation. Following on from this, as such, BAV should only
take place in tertiary centres where the facility for
‘bail-out’ therapy including surgery/TAVI is available
and where there is sufﬁcient operator expertise in the
procedure.
BAV PROCEDURAL CONSIDERATIONS
BAV can be undertaken under local or general anaes-
thetic using ﬂuoroscopic guidance with or without the
aid of TOE. Most procedures are performed using a
standard retrograde technique (ﬁgure 2) via the
femoral artery and rarely, in the presence of severe arter-
ial disease, the brachial artery or subclavian artery (via
arterial cut-down) can be used. The use of an antero-
grade trans-septal approach has also been described in
cases where retrograde arterial access is not possible.14
During BAV, an arterial sheath is percutaneously
inserted, most commonly into the femoral artery. The
size of the arterial sheath varies between 8 and 12
French depending on the aortic balloon size and manu-
facturer. For smaller arterial sheath sizes, a vascular
closure device such as an Angioseal, Exoseal or Proglide
may be deployed at the end of the procedure to achieve
arterial haemostasis. For larger sheath sizes (usually
>8 Fr sheaths), a Proglide or Prostar may need to be pre-
deployed prior to arterial sheath insertion and
Figure 2 (A–C) Sequential angiographic images demonstrating placement of the wire, using the retrograde technique in the LV
cavity (A), followed by balloon placement (B) and subsequent dilation within the calcified aortic valve (C). LV, left ventricular.
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procedure initiation to allow suitable closure at the end
of case. Furthermore, vascular complications can be
minimised by the use of preclosure devices (Perclose,
ProGlide or Prostar, Abott Vascular), appropriate preas-
sessment of peripheral vascular status and use of micro-
puncture techniques.
In most cases of BAV, venous access is also needed to
facilitate temporary pacing wire (TPW) insertion for
overdrive pacing to stabilise balloon positioning during
inﬂation by decreasing the cardiac output and displace-
ment forces on the balloon. With some non-compliant
balloon proﬁles, overdrive pacing is not essential such as
the ‘True Dilatation’ Balloon (Bard Vascular). If patients
already have a permanent pacemaker in situ, then over-
drive pacing via the permanent system is possible. TPWs
can be inserted via the internal jugular vein, femoral
vein or the subclavian vein. Advantages of internal
jugular or subclavian TPW insertion include reduced risk
of infection, Deep Vein Thrombosis (DVT) and allowing
patient mobility in the postoperative period if the patient
is pacing dependent. In a series of 423 patients, TPW use
did not demonstrate any effect on either mortality or
complication rates.15
Patients are systemically anticoagulated with heparin at
75–100 U/kg to achieve an Activated Clotting Time
(ACT) of 250–300 s. Following this, a diagnostic catheter
with the soft-tip straight end of a standard 0.035 guide-
wire is used to probe and cross the aortic valve. Typical
catheters used to help direct the guidewire towards the
aortic oriﬁce include the Judkins Right 4 ( JR4) or
Amplatz Left 1 (AL1) but other catheters can be used
including the Amplatz Left 2 (AL2—particularly where
there is a horizontal aortic root/vertical conﬁguration of
the aortic valve) or Amplatz Right 1 (AR1) catheter.
Gentle clockwise or anticlockwise rotation of the cath-
eter may be needed to orientate the guidewire in line
with aortic oriﬁce. If the guidewire is unable to negoti-
ate the aortic valve oriﬁce, then a hydrophilic Terumo
guidewire (Terumo, Kanagawa, Japan) may be used to
help cross the aortic valve. The aortic valve can be
crossed in the standard anteroposterior projection or a
typically with 10–20° of Left Anterior Oblique (LAO)
angulation may be applied to open up the aortic root
and to provide the operator with an improved under-
standing of the oriﬁce location.
Once a guidewire has crossed the aortic valve, then
the coronary catheter can be advanced into the LV
cavity and exchanged via a J-tipped long exchange
guidewire to a pigtail catheter into the LV cavity.
Simultaneous transduction of the pigtail catheter and
the side port of the femoral arterial sheath will allow an
assessment of differences in LV pressure to peripheral
femoral arterial pressure and thereby an estimate of
transvalvular gradient. An alternative is the use of a dual-
lumen pigtail catheter which allows for the simultaneous
measurement of central aortic pressures and LV pres-
sures without the need for transducing a side port
femoral sheath and is more accurate for assessing
central arterial/aortic pressures and is not contaminated
by peripheral arterial disease as is the case for femoral
arterial pressure transduction.
An exchange length ‘superstiff’ guidewire such as a
preshaped Amplatz superstiff guidewire, Safari wire
(Boston Scientiﬁc) or Conﬁda wire (Medtronic) which
have an atraumatic curve on their distal end can then be
exchanged for the pigtail catheter and positioned at a
suitable position in the LV apex to support passage of
the aortic balloon across the annulus (ﬁgure 2). Ideally,
the wire should be suitably placed in a position that
does not interfere with the mitral valve apparatus and is
not too arrhythmogenic in terms of ectopy inducing. An
Right Anterior Oblique (RAO) projection can be used
to ensure suitable apical positioning of the superstiff
guidewire, and is desirable for minimising any inter-
action with the mitral valve apparatus.
Aortic balloon size is usually predetermined based on
Trans-Thoracic Echocardiography (TTE), TOE or CT
assessments of annular diameter. Most operators will size
the aortic balloon closely to the measurement of the
aortic valve annulus diameter upto a 1:1 ratio depending
on clinical and echocardiographic and CT features such
as the gradient across the valve, patient tolerability of pro-
cedure, presence of cardiogenic shock and calciﬁcation
in the left ventricular outﬂow tract (LVOT) and valvular
apparatus and degree of pre-existing AR. On TTE or
TOE, the aortic annular diameter is measured from the
aortic annulus measurement or LVOT measurement in
systole in the parasternal long axis view and the balloon
is sized accordingly up to a 1:1 ratio compared with
annular diameter or at maximum a 10% oversize to the
LVOT diameter. Balloon sizing tends to be more aggres-
sive where BAV is used as a stand-alone therapy or as a
diagnostic tool to assess therapeutic response to reduc-
tion in transaortic gradients, than when it is used for pre-
dilation in TAVI. It is important to ensure a balloon size
smaller than the sinotubular junction diameter.
Aortic balloons typically range between 3 and 6 cm in
length and have a variable diameter to ﬁt different
annular dimensions (ﬁgure 2). They are ﬁlled with a
mixture of contrast and saline (usually in a ratio of 90:10
to appear radio-opaque on ﬂuoroscopy and allow rapid
deﬂation) and de-aired prior to use. They have a vari-
able volume of 25–60 mL dependent on balloon diam-
eter and length. Operators can use semicompliant
(Tyshak II, Braun International Systems) or non-
compliant aortic balloons (Z-Med, Braun International
Systems; Maxi LD Balloon, Cordis Corporation).
Semicompliant balloons tend to have a lower proﬁle and
therefore require smaller vascular access sheaths which
helps with reduced vascular complications in this elderly
cohort. The trade off, however, is that they have less pre-
dictable inﬂation diameters than the non-compliant bal-
loons and have lower rated burst pressures.
Once the balloon is positioned across the aortic
annulus, then overdrive pacing is started. Patients are
usually overdrive paced at 180–220 bpm to allow a drop
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in the stroke volume. Once a drop in transduced arterial
blood pressure is demonstrated, the balloon position
should be conﬁrmed to be unchanged and then it
should be rapidly inﬂated typically a few seconds (usually
∼3 s) prior to rapid balloon deﬂation and discontinu-
ation of overdrive pacing. The balloon should then be
withdrawn into the ascending aorta from the aortic
annulus to allow recovery of systemic blood pressure. The
operator watches to ensure on ﬂuoroscopy the appear-
ance of a fully inﬂated balloon across the aortic annulus.
The different aortic balloons employed are designed
to inﬂate to predictable diameters at set pressures. The
increase in BAV procedures being performed has
resulted in an evolution in the design of these balloons
in order to improve both the safety and technical
aspects of the procedure. Current generation balloons
have changed from a cylindrical shape to an hourglass
shape (V8: InterValve, NuCLEUS: NuMed, NuCLEUS-X:
NuMed and Braun), to improve balloon positioning and
stability during device inﬂation, whereby the shape is
maintained throughout inﬂation reducing the likelihood
of annulus rupture.
After balloon inﬂation the transvalvular gradient can
be assessed on both echocardiography (TTE or TOE) as
well as invasively by repositioning a pigtail catheter into
the LV to decide on the need for further balloon inﬂa-
tions or an increment in balloon diameter to achieve a
therapeutic effect with BAV which is usually a 40–50%
reduction in peak aortic valve gradient with no signiﬁ-
cant increase in AR. Further balloon inﬂations should
not take place until blood pressure has returned back to
baseline. A signiﬁcant increase in LV end diastolic
pressure or a drop in the aortic diastolic pressure is sug-
gestive of haemodynamically signiﬁcant AR.
On case completion, the operator can remove the
arterial access (by vascular closure device or manual pres-
sure if ACT<150 s) and the TPW can be removed depend-
ing on the likelihood of bradycardia development. The
patient can then be recovered in a Coronary Care Unit
(CCU) or monitored cardiac ward and can often be dis-
charged the following day based on clinical state and a
repeat echocardiogram to assess aortic valve area, gradi-
ents and any AR.
In an antegrade approach, there is a trans-septal punc-
ture (via a trans-septal needle and Mullins sheath) and
an extended wire loop that is from the right side of the
heart, across the interatrial septum into the left side of
the heart and across the aortic valve. An Inoue balloon
(Toray) can be used to dilate the aortic annulus. While
the antegrade approach reduces the need for large
calibre arterial access in patients with peripheral vascular
disease, it is associated with higher risk of damage to
mitral valve apparatus.
Where patients are being considered for a bridge to
deﬁnitive therapy, whether it is TAVI or AVR, they should
be reviewed in clinic within 4–6 weeks to make a
decision.
Procedural aims
During balloon dilation of the aortic valve, most opera-
tors aim for a reduction in mean transaortic valvular gra-
dient of 50 mm Hg or 40–50% of the original gradient,
with variations arising depending on clinical circum-
stances (ﬁgure 3A, B). Saia et al10 reported the complete
Figure 3 (A and B) Pressure tracings showing haemodynamic results pre-BAV (A) and post-BAV (B) procedure. Pre-BAV, there
is a significant transvalvular gradient of 72 mm Hg and haemodynamically significant aortic stenosis. Post-BAV simultaneous
aortic-LV pressure assessment demonstrates a significant reduction in transvalvular gradient to 13 mm Hg demonstrating
therapeutic efficacy of the BAV. Incidentally, there is a new onset of Left Bundle Branch Block (LBBB) post-BAV in this patient as
demonstrated by prolongation of the QRS duration on the rhythm strip on top. This may be a transient phenomenon and
rate-related postburst pacing or may be permanent due to anatomical proximity of the AV node and conduction tissue to the
aortic annulus. AV, atrioventricular; BAV, balloon aortic valvuloplasty; LV, left ventricular.
Keeble TR, Khokhar A, Akhtar MM, et al. Open Heart 2016;3:e000421. doi:10.1136/openhrt-2016-000421 5
Interventional cardiology
abrogation of the aortic pulse for a few seconds follow-
ing three manual dilations as a sufﬁcient end point.
Subtle changes that may be evident post-BAV that
suggest improved haemodynamics include an increase
in aortic systolic arterial pressure and a rapid upstroke to
arterial waveform. Any reductions in transvalvular gradi-
ent has to be off-set against the increased risk of AR and
annular rupture from large and more aggressively sized
balloon diameters or sequential dilations.
COMPLICATIONS POST-BAV
Patients can experience a variety of complications post
including vascular haemorrhage (external haematoma,
retroperitoneal haemorrhage), bradycardia (complete
atrioventricular block, pauses), tamponade (from tem-
porary wire insertion), aortic annular rupture, pump
failure (acute LV systolic failure), severe AR, acute severe
mitral regurgitation (from guidewire/pigtail entrapment
of Mitral Valve (MV) apparatus or balloon disruption),
coronary ischaemia or sustained tachyarrhythmia
(Ventricular Tachycardia (VT)). It is important to treat
hypotension promptly as this patient population toler-
ates hypotension particularly poorly and fall into a
vicious cycle of hypotension and coronary ischaemia.
Hypotension should be treated with intravenous ﬂuid
administration together with inotropes or vasopressors
while the cause for hypotension can be identiﬁed imme-
diately and treated. This usually involves an algorithm of
possibilities assessed by live ECG analysis intraprocedu-
rally, TTE (or TOE) to look for annular rupture, AR or
tamponade, iliofemoral angiogram and aortogram on
ﬂuoroscopy to assess for contrast extravasation.
Vascular haemorrhage: This can be treated by a periph-
eral vessel occlusion balloon, replacement of lost intra-
vascular volume with ﬂuids and blood products, reversal
of anticoagulation and surgery or peripheral vascular
covered stenting if needed.
Bradycardia: Can be treated by intravenous atropine
and temporary pacemaker wire use.
Tamponade: This complication can be treated with
emergency pericardiocentesis, reversal of anticoagula-
tion, intravascular ﬁlling with ﬂuids and blood products
and if ongoing bleeding then cardiothoracic surgery.
Severe AR: In certain cases, rescue manoeuvres can be
used to mobilise a ﬁxed cusp of the aortic valve.16
Otherwise inotropes, diuresis and stabilisation may be
appropriate. Rapid pacing via the TPW may also limit the
diastolic regurgitation. Generally signiﬁcantly hypertro-
phied hearts (as in AS) do not tolerate acute AR well and
in such cases urgent TAVI or surgery may be required.
Annular rupture: This has a very high mortality rate
given the nature of the complication and most patients
acutely deteriorate and die on table. If annular rupture
is promptly recognised, then intravenous ﬂuid therapy,
treatment of tamponade and emergency cardiothoracic
surgery, if appropriate is needed to maximise chances of
survival.
HISTOPATHOLOGY OF AORTIC VALVE FOLLOWING BAV
The pathology of calciﬁc AS in the elderly is due to
ﬁbrosis and calciﬁcation of the valve leaﬂets, which is
sometimes associated with commissural fusion. These
pathological changes render the valve rigid and
immobile.
The mechanisms of successful percutaneous balloon
dilation of the aortic valve described by Serruys and col-
leagues in 1993 include (1) cleavage or laceration of the
dense collagenous valve stroma, (2) fracture and/or
fragmentation of calciﬁcations and (3) separation of
fused commissures. They described that the ﬁnal
outcome of balloon dilation mainly depends on the
severity of the underlying pathological abnormalities in
the valve and the extent of the injury created by the
balloon. BAV causes injury to the aortic valve which
leads to the development, organisation and collagenisa-
tion of young scar tissue in the tears and fractures in the
valve which ultimately leads to progressive reduced
leaﬂet mobility and restenosis.17
HAEMODYNAMIC OUTCOMES
The National Heart Lung and Blood Institute (NHLBI)
balloon valvuloplasty registry collected data on patients
undergoing BAV in the USA and Canada between 1987
and 1989, and forms the most comprehensive early
outcome data set.18 In 1991 the group published 30-day
follow-up on a cohort of 674 patients. Haemodynamically
post-BAV, aortic valve area increased from 0.5 to 0.8 cm2
(p<0.0001), with a concomitant decrease in peak aortic
gradient from 65 to 31 mm Hg (p<0.0001), associated
with a small but signiﬁcant increase in cardiac output.
Similar results were reported from the Mansﬁeld
Scientiﬁc Aortic Valvuloplasty Registry of 492 patients
between 1986 and 1987 where an increase in aortic valve
area from 0.5 to 0.8 cm2, a decrease in peak aortic gradi-
ent from 60 to 30 mm Hg and an increase in cardiac
output from 3.86 to 4.05 L/min was observed.19
The Mansﬁeld registry assessed the impact of
procedure-related variables on acute valvuloplasty and
postvalvuloplasty haemodynamic changes. The only vari-
able associated with a signiﬁcant difference was balloon
inﬂation time whereby an inﬂation time between 30 and
60 s resulted in a larger ﬁnal aortic valve area, but no
difference in aortic valve gradient when compared with
inﬂation times of <30 s. They concluded that short inﬂa-
tion times (<30 s) should be avoided.19 The size of
largest balloon used, the number of balloons, the
number of balloon exchanges and the use of single or
double balloons made no signiﬁcant difference to post-
procedure haemodynamics. A summary of haemo-
dynamic outcomes from different studies during the
pre-TAVI era can be found in table 3.
Outcome data from the ‘pre-TAVI era’
Procedural complications include systemic embolisation,
acute AR, ventricular perforations, local arterial trauma,
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Table 3 Reported changes in aortic gradient and aortic valve area following BAV procedures in series reported prior to and
after the introduction of TAVI in 2002
Era Author Year Study design Patients
Change in aortic
gradient (mm Hg)
Change in aortic
valve area (cm2)
No TAVI (pre-2002) Lababidi et al29 1984 SC, P 23 81 NA
Walls et al30 1984 SC, P 27 90 NA
Block and Palacios31 1987 SC 35 45 0.44
Dorros et al32 1987 SC 10 38 0.30
Schneider et al33 1987 SC 6 27 0.39
Isner et al34 1987 SC 9 15 0.26
McKay et al35 1987 SC, P 9 36 0.47
Cribier et al36 1987 SC 92 33 0.30
Letac et al37 1988 SC 218 35 0.30
Nishimura et al38 1988 SC, P 25 26 0.20
Litvack et al39 1988 SC 25 15 0.31
Safian et al40 1988 SC 170 43 0.41
NHLBI Registry18 1991 MC, R 674 34 0.30
Mansfield Registry19 1991 MC, P 492 30 0.32
Lieberman et al41 1995 SC 165 30 0.20
TAVI (2002 to current) Agarwal et al42 2005 SC, R 212 26 0.59
Klein et al43 2006 SC, R 78 21 0.38
Tissot et al21 2011 SC, P 253 16 0.21
Khawaja et al15 2013 MC 423 50 0.22
Ben-Dor et al22 2013 SC, P 472 23 0.40
Saia et al10 2013 SC, R 415 30 0.30
Eltchaninoff et al44 2014 SC, R 323 23 0.44
Moretti et al23 2015 MC, R 811 21 0.19
BAV, balloon aortic valvuloplasty; MC, multicentre; NA, not available; NHLBI, National Heart Lung and Blood Institute; P, prospective; R,
retrospective; SC, single-centre; TAVI, transcatheter aortic valve implantation.
Table 4 Reported complications from series of patients undergoing BAV prior to and after the introduction of TAVI in 2002
Era Author Subgroup Year
Study
design Patients
Total
complication CVA CT
Acute
AI MI Vascular*
No TAVI
(pre-2002)
NHLBI
Registry18
NA 1991 MC, R 674 25% 2% 1% 1% NA 34%
Mansfield
Registry19 20
NA 1991 MC, P 492 21% 2% 2% 1% NA NA
Lieberman
et al41
NA 1995 SC 165 NA 0.4% NA 1.1% NA NA
TAVI (2002
to current)
Agarwal
et al42
NA 2005 SC, R 212 NA 0.4% NA 1.1% NA 13.5%
Klein et al43 NA 2006 SC, R 78 22% 1% 1% 0% 1% NA
Tissot et al21 NA 2011 SC, P 253 4% 0% NA 0% 0% 1%
Khawaja
et al15
NA 2013 MC 423 6.3% 1% 1% NA 1% 2.2%
Ben-Dor
et al22
NA 2013 SC, P 472 NA 2% 1% 1% 0% 11%
Saia et al10 NA 2013 SC, R 415 NA 1% NA 2.6% 0% 5.6%
Eltchaninoff
et al44
NA 2014 SC, R 323 7% 2% 0% 2% 0% 2.5%
Moretti
et al23
Dest. 2015 MC, R 416 NA 0.8% NA NA 2.4% 11%†
B-TAVI 320 NA 0.7% NA NA 0.8% 7.7%†
B-AVR 75 NA 0% NA NA 0% 12%†
*Includes both major and minor vascular complications as well as requirement for blood transfusions.
†According to VARC criteria.
AI, aortic insufficiency; BAV, balloon aortic valvuloplasty; B-AVR, bridge to aortic valve; B-TAVI, bridge to TAVI; CT, cardiac tamponade; CVA,
cerebrovascular accident; Dest, destination therapy; MC, multicentre; MI, myocardial infarction; NA, not available; NHLBI, National Heart Lung
and Blood Institute; P, prospective; R, retrospective; SC, single-centre; TAVI, transcatheter aortic valve implantation; VARC, Valve Academic
Research Consortium Definitions.
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arrhythmias and cardiac arrest. Data from the NHLBI
and Mansﬁeld registries as well as other studies are sum-
marised in table 4 below.
Additional complications included the need for blood
transfusion (23%), vascular surgery (7%), cerebrovascu-
lar accident myocardial infarction (MI; 2%) and cardiac
surgery (1%). Severe AR is relatively uncommon follow-
ing BAV, and occurred in only 11 (1%) patients across
both cohorts, leading to surgery in 8 (including 3
patients emergently) and death in 2. The Mansﬁeld
study demonstrated an increased propensity towards
acute AR in women in whom a dual balloon technique
was used.20
In the NHLBI study, by 30 days there were 92 deaths
(14%), 71 due to cardiovascular-related causes.
Unsurprisingly, death was more common in those
patients with preprocedural poor LV systolic function,
low cardiac output (<3 l/min), hypotension, New York
Heart Association (NYHA) IV cardiac failure and multi-
organ failure.
Of the survivors (86%) at 30 days, symptomatic
improvement was generally seen, with 75% experiencing
at least one functional class improvement in overall
NYHA score.18
BAV in the ‘TAVI era’
With the advent of TAVI, the clinical status and baseline
characteristics of patients undergoing BAV has changed
substantially over the past 10 years. Advances in technol-
ogy coupled to improved patient selection has led to
improvements in procedural outcomes and complica-
tion rates. These are described in detail below and are
compared with historical pre-TAVI data in tables 3–5
below.
Tissot et al21 describe a cohort of 253 patients referred
to their centre for TAVI between 2006 and 2009.
Forty-one patients (16%) were considered transiently
unsuitable for either AVR or TAVI and underwent BAV as
a bridge to intervention (half of which were in cardio-
genic shock). Of the other patients, TAVI/AVR was per-
formed in 140 cases and medical therapy alone in 72
cases. Within the BAV treated group, there were no
Percutaneous Aortic Balloon Valvuloplasty
(PABV)-related deaths. Of these 41 patients, 23 went on
to have TAVI (n=19), or AVR (n=4), while 18 patients
did not undergo further intervention. In those who
underwent deﬁnitive aortic valve intervention with TAVI
or AVR, the 1-year and 2-year survival rates were 94±5%
and 85±10%, respectively. One-year and 2-year survival
rates of 33±11% and 6±5% after BAV alone were similar
to those who were managed medically.2 21 Thus, the
Tissot et al’s paper supports the concept of patients
undergoing BAV to improve haemodynamics and clinical
status at relatively low procedural risk, with a view to
more deﬁnitive treatment based on their clinical
response and comorbid conditions.
Saia et al10 reported on a series of 415 consecutive
patients who underwent BAV between 2000 and 2010 in
Italy. Of the 415 patients, 23 were in cardiogenic shock
and 133 were treated for symptom palliation alone, the
remaining 259 were treated with a view to subsequently
being considered for AVR or TAVI. Saia et al described
only occasional requirement for right ventricular pacing
and at least three dilations with complete pulse abroga-
tion was achieved in 79.8% of patients. In terms of
overall procedure success as measured by reduction in
peak LV to aortic pressure gradient, the following was
reported: >50% gradient reduction was achieved in 215
patients (51.8%), 30–49% reduction in 105 (25.3%) and
<30% in 95 patients (22.9%). Acute AR occurred in 11
patients (2.6%), but it was successfully managed in 8
patients in the catheter laboratory, using a pigtail cath-
eter, reinforced with a stiff wire to mobilise a locked
cusp. The in-hospital mortality of the entire cohort was
5.1% and occurred predominantly in patients with car-
diogenic shock (56.5% vs around 2% in other sub-
groups). The incidence of stroke was 0.5% (two patients,
one with complete functional recovery), while life-
threatening bleeding occurred in 1.5% and major vascu-
lar complications in 2.2%. Postprocedure, acute kidney
injury was seen in 18% of cases, with an at least 50%
increase in creatinine reported in 10% of cases.10 22 The
1-year and 2-year mortality rates were 33.2% and 57.4%,
respectively, with the highest incidence in the shock
group (70.7% and 80.4%). Those who underwent BAV
for symptom palliation alone had 1-year and 2-year mor-
tality rates of 44.3% and 67%. Repeat BAV procedures
were performed in 30.8% within 2 years of the index
procedure. The clinical outcomes in those who under-
went TAVI were good, with a 1-year mortality of 13.1%
and of 19.4% at 2 years. Patients who underwent AVR
had corresponding mortalities of 0% and 33.7%.10 In
those patients presenting with cardiogenic shock, 11%
underwent AVR with nobody undergoing a TAVI.10
Given that the outcomes for those treated with BAV
alone are poor, patients being bridged should have
minimal delay prior to their destination therapy on
improvement of clinical status.
Recently, the largest published series reported on 811
consecutive patients undergoing BAV across seven
centres in Europe between 2006 and 2013.23 Nearly half
the cohort underwent BAV with the intention of bridg-
ing to TAVI (n=320, 40%) or AVR (n=75, 9%), with the
remainder being treated as destination therapy. Of those
being bridged to TAVI or AVR, 65.1% and 68.4%,
respectively, did not have any further intervention, per-
cutaneous or surgical, after their BAV procedure. Those
undergoing BAV as a bridge to AVR were younger and
had a reduced burden of comorbidities, but there were
no signiﬁcant difference in the echocardiographic fea-
tures of AS between the three groups. 30-day all-cause
mortality (6.5% vs 6.2% vs 7.4%; p=0.56) and cardiovas-
cular mortality (4.9% vs 4.9% vs 2.9%; p=0.98) was not
statistically different among the three groups of destin-
ation therapy versus TAVI versus AVR, respectively. After
a median follow-up of 318 days (IQR 116–500 days) no
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statistical difference in all-cause mortality was seen
between the three groups, but cardiovascular deaths
were reduced for patients undergoing AVR (11% vs 11%
vs 3%; p=0.04). Life-threatening and major bleeding
(8% vs 5.7% vs 6%) and vascular complication (3% vs
2% vs 6%) rates were higher than reported in Saia et al’s
cohort but MI (1.6% vs 0.8% vs 0%) and stroke rates
(0.8% vs 0.7% vs 0%) were comparable.23 For all compli-
cations, the Valve Academic Research Consortium
Deﬁnitions (VARC) criteria were used.24
The trend towards reduced complication rates
observed during the TAVI era was also observed in a
cross-sectional study of all BAVs performed in the USA
between 1998 and 2010. In-hospital mortality rates fell
from 11.5% in 1998 to 8.8% in 2009–2010, with similar
improvements seen in complication rates in comparison
to date from the Mansﬁeld and NHLBI registries.25
These trends could be explained by improvements in the
technology of the balloons, catheters and vascular
closure devices, as well as the increased screening of the
peripheral arterial system.26 27 Additionally, more proce-
dures are now being undertaken in high-volume centres
by increasingly experienced operators following an MDT
discussion highlighting the importance of appropriate
selection of patient based on characteristics and
comorbidities.25 Use of novel clinical risk prediction
scores, may lead to further improvements in the future.28
Combined BAV and PCI
Given the rising incidence of coronary artery disease
and severe AS, around 65% of patients referred for TAVI
are found to have coexisting coronary artery disease.46
Studies comparing patients undergoing concomitant
BAV and percutaneous coronary intervention (PCI)
Table 5 Cumulative all-cause mortality following BAV in series reported prior to and after the introduction of TAVI in 2002
Era Author Subgroup Year
Study
design Patients Hospital* 30-day 6-month 1-year 5-year
No TAVI
(pre-2002)
Lababidi et al29 NA 1984 SC, P 23 NA NA NA NA NA
Walls et al30 NA 1984 SC, P 27 4% NA NA NA NA
Block and
Palacios31
NA 1987 SC 35 6% NA NA NA NA
Dorros et al32 NA 1987 SC 10 NA NA NA NA NA
Schneider et al33 NA 1987 SC 6 0% NA NA NA NA
Isner et al34 NA 1987 SC 9 NA NA NA NA NA
McKay et al35 NA 1987 SC 32 10% NA NA NA NA
Cribier et al36 NA 1987 SC 92 3% NA NA NA NA
Letac et al37 NA 1988 SC 218 5% NA NA NA NA
Nishimura et al38 NA 1988 SC, P 25 1% 16% 48% NA NA
Litvack et al39 NA 1988 SC 25 1% NA NA NA NA
Safian et al40 NA 1988 SC 170 4% NA 18% 26% NA
NHLBI Registry18 NA 1991 MC, R 674 3% 14% NA 36% NA
Mansfield
Registry19 45
NA 1991 MC, P 492 5% NA 23% 36% NA
Lieberman et al41 NA 1995 SC 165 NA NA NA 40% NA
TAVI (2002
to current)
Agarwal et al42 NA 2005 SC, R 212 8% 10% NA 36% 86%
Klein et al43 NA 2006 SC, R 78 1% NA NA 62% 86%
Tissot et al21 BAV alone 2011 SC, P 41 NA NA NA 67% NA
BAV
bridge
140 NA NA NA 6% NA
Khawaja et al12 NA 2013 MC 423 2.4% 14% NA 36% NA
Ben-Dor et al22 NA 2013 SC, P 472 2.5% NA NA NA NA
Saia et al10 B-TAVI 2013 SC, R 162 NA NA NA 21% NA
B-AVR 197 NA NA NA 22% NA
Shock 23 NA NA NA 71% NA
Pall. 133 NA NA NA 44% NA
Eltchaninoff et al44 BAV 2014 SC, R 238 NA NA NA 54% 99%
B-TAVI 54 NA NA NA 26% 91%
B-AVR 31 NA NA NA 23% 81%
Moretti et al23 Dest. 2015 MC, R 416 NA 6.5% NA NA NA
B-TAVI 320 NA 6.2% NA NA NA
B-AVR 75 NA 7.4% NA NA NA
*Hospital: mortality rate during procedure, after 24 hours and at time of discharge combined.
BAV, balloon aortic valvuloplasty; B-AVR, bridge to AVR; B-TAVI, bridge to TAVI; Dest., destination therapy; MC, multicentre; NHLBI, National
Heart Lung and Blood Institute; P, prospective; Pall., palliation; R, retrospective; SC, single-centre; TAVI, transcatheter aortic valve
implantation.
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against those undergoing BAV alone have not demon-
strated any difference in hospital mortality or complica-
tion rates between both groups, although an increased
length of stay was seen for those undergoing both proce-
dures simultaneously.47 48 Furthermore, no difference
was observed in the efﬁcacy of the valvuloplasty, leading
to Ben-Dor et al48 to postulate that the added beneﬁt of
revascularisation protects against LV ischaemia, particu-
larly during rapid right ventricular pacing.
Balloon postdilation in TAVI
One of the complications of percutaneous aortic valve
implantation is that of paravalvular AR or paravalvular
leak (PVL). This acute regurgitant volume is poorly tol-
erated and the LV is not able to adapt resulting in dele-
terious progressive dilation, a rapid increase in the LV
end diastolic pressure and the onset of pulmonary
oedema.49 In the original PARTNER trial, 12% of TAVI
cases had postprocedural moderate-to-severe AR despite
procedural intervention at 30-day follow-up and 7% of
cases had persistent AR at 1-year follow-up.6 Owing to
the resultant worse outcomes in patients with signiﬁcant
PVL, the presence and severity of AR is checked for judi-
ciously intraprocedurally by means of transthoracic/
transoesophageal echocardiography, aortography and
invasive haemodynamic assessment.50 Paravalvular AR is
most often only mild or mild-to-moderate in severity
post-TAVI. These patients do not require any speciﬁc
further intervention and often have ongoing echocar-
diographic surveillance of the AR severity in the post-
operative phase and on discharge. At 1-year follow-up
post-TAVI, 80% of patients had trace or mild AR and
13% of patients had no AR.6 A recent literature review
on TAVI, self-expanding THV valves (Corevalve,
Medtronic) were associated with higher rates (9–21%)
of haemodynamically important (moderate-to-severe)
AR compared with balloon-expandable (Edwards Sapien
XT) valves (6–13.9%).50
Several causative factors have been implicated in con-
tributing to the incidence of PVL in patients post-TAVI.
This includes the presence of signiﬁcant valvular
annular and LVOT calciﬁcation, valve underexpansion,
THV undersizing and suboptimal positioning of THV
(either too low in the LVOT or too highly positioned).
Attempts have been made to reduce the inﬂuence of
these factors by improving TAVI technology with balloon
predilation of the native aortic valve prior to valve
deployment intraprocedurally, development of THV
cuffs that reduce the degree of PVL, the presence of
repositionable valves and the increasing use of CT to
accurately assess annulus area to improve decision-
making in THV sizing.
Haemodynamic assessment of PVL
Haemodynamic assessment can be undertaken to assess
the severity of PVL. The Aortic Regurgitation Index
(ARI) is calculated by subtracting the Left Ventricular
End-Diastolic Pressure (LVEDP) from the aortic diastolic
blood pressure and dividing this by the aortic systolic
blood pressure. An ARI of 25 is used as the cut-off value
for the predictor of 1-year mortality and a score of ≥25
is suggestive of non-signiﬁcant PVL.51 This haemo-
dynamic assessment should be undertaken at least
10 min post-THV deployment to allow recovery of the
myocardium from the impact of burst pacing inﬂuen-
cing haemodynamic parameters.52
The treatment of moderate signiﬁcant AR post-TAVI
depends on the cause. If the mechanism of AR is due to
valve underdeployment or due to eccentric annular cal-
ciﬁcation then balloon postdilation may be used to
expand the valve further (in self-expanding and
balloon-expandable THVs) and reduce any paravalvular
AR.53 Postdilation of THV can be safely undertaken with
an oversized balloon without causing signiﬁcant damage
to the THV prosthesis. This is the initial therapeutic
strategy to reduce the severity of postprocedural para-
valvular AR.53 Postdilation reduces the severity of AR in
a signiﬁcant proportion of patients.54
In a cohort of patients with self-expanding THV
implant (Corevalve), independent predictors of moder-
ate+ AR (AR≥2+) were peripheral vascular disease,
larger aortic annulus dimensions and low implantation
depth of THV. In this study, 32 out of 79 patients
(40.5%) had postprocedural AR≥2+. In 10 patients, the
AR was conservatively managed. In the remainder AR
patients, 21 underwent BAV with a majority of them
improving in AR severity (17/21 or 81%). In the remain-
ing four patients, AR severity failed to improve with BAV
and two required a valve-in-valve implantation and in
one case the original THV was pulled more proximally
via a snare technique. This shows that postdilation is an
effective measure to reduce the severity of AR.55
Postdilation has been shown to increase the minimum
diameter of the THV on average by 1.9 mm. Postdilation
also improves the circularity of the THV and improves
apposition of the aortic valve annulus and THV
cuff.54 56 Different operators will use a variety of balloons
for THV postdilation based on their experience, the
degree of paravalvular AR, percentage of THV oversizing
or undersizing, severity of calciﬁcation of native valves
and LVOT and the initial deployment pressure (if a
balloon-expandable valve is used). Frequently in
balloon-expandable valves, the deployment balloon may
be reused based on the relevant manufacturer. A semi-
compliant balloon could be used to postdilate the valve
in a 1:1 ratio to the mean annulus size. If a non-
compliant balloon is used, then this is usually at least
1 mm smaller than the mean aortic annulus to achieve
satisfactory postdilation while balancing against the risk
of annular rupture. The advantage of using the same
inﬂation balloon for postdilation as used for THV
deployment (if it was used in balloon-expandable valves)
is that it avoids transit of another balloon across the
aortic arch/descending aorta to minimise the risk of
aortic plaque disruption or dislodgement. In a study by
Hahn et al,57 balloon postdilation was undertaken under
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rapid pacing with the same inﬂation volume as the
initial deployment volume or in some cases with 0.5–
2 mL extra in the inﬂation syringe as per operator dis-
cretion. In their cohort, the postdilation balloon was
usually placed in a slightly more apical position to help
better THV deployment around the aortic annulus to
seal any cuffs.
In summary, paravalvular AR is associated with
increased morbidity and mortality. The newer iterations
of the THV including the Edward Sapien S3 and
Corevalve Evolut-R are associated with reduced inci-
dence of paravalvular AR. When paravalvular AR is
present it is important to assess the haemodynamic
impact of the AR and mechanism of AR to determine
the best possible solution which may include valve repo-
sitioning, THV postdilation or valve-in-valve
implantation.
CONCLUSION
In the TAVI era, BAV has an important role to play in
the management of patients with severe symptomatic AS
deemed too high risk for AVR either because of
comorbidities or clinical instability. It has been used for
symptom palliation and as a salvage procedure in the
context of cardiogenic shock since it was ﬁrst performed
in 1986, but over the past 10 years, it has been used with
increasing frequency as a bridge to deﬁnitive aortic valve
intervention, usually TAVI but also AVR. In those with
heart failure and severe impairment of LV function, BAV
can improve clinical status to reduce the risk of subse-
quent TAVI/AVR and has also proved useful in patients
where the beneﬁts of deﬁnitive aortic valve intervention
are unclear due to comorbidities such as COPD or other
frailty. Although BAV procedural risks and complications
remain, these have improved since the advent of TAVI
programmes due to improvements in technology, oper-
ator experience and more careful patient selection.
The advent of increased technology in the TAVI era
has resulted in improved range of devices that can be
used for the BAV procedure. Prior to the TAVI era most
LV superstiff guidewires required shaping by the oper-
ator to ensure a rounded edge in the left ventricle to
reduce the risk of chamber perforation. Now the pres-
ence of conﬁda and safari wires used during TAVI proce-
dures can also be used for BAV and provide a safe,
atraumatic and less arrhythmogenic support guidewire
for BAV. Improvement in CT techniques and availability
of this resource means that better assessments of aortic
annular diameter and peripheral vascular assessment
can be made prior to the BAV procedure. As well as
this, improvement in balloon shapes with ‘hour glass’
shape means more accurate balloon positioning,
reduced risk of annular rupture due to a narrowed
balloon waist and improved aortic valve areas due to
leaﬂet hyperextension.
Limitations into the efﬁcacy of BAV include that the
data reviewed are predominantly retrospective and
observational in nature. Given the patient population,
there is a heterogeneous range of comorbidities or
characteristics that can affect outcome including mortal-
ity. Further controlled or randomised studies as well as
data on cost-effectiveness would equip both physicians
and policymakers with a greater understanding of the
treatment risks, beneﬁts and economic costs in relation
to the natural history of the disease.
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